Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 17, 2006. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, rather than a comprehensive financial results report.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the transaction price of $54.65 per share for Ordinary Shares ADRs.
Material Changes
The document reports a specific increase in shareholding interest by Dr. D. Pulman. There is no information provided regarding material changes in the company's financial position or operations compared to prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, risk factors, or discussion of contingencies. It strictly details a transaction notified under Disclosure Rule 3.1.4R(1)(a) regarding the GlaxoSmithKline Annual Investment Plan.
Key Facts for Investor Verification
- Dr. D. Pulman increased his interest in Ordinary Shares ADRs by 2,112.946 shares.
- The transaction price was $54.65 per share.
- The transaction was executed through the GlaxoSmithKline Annual Investment Plan.
- The notification was issued on March 17, 2006, by Company Secretary S. M. Bicknell.